Supports Heart Health Research shows potential benefits for people with heart conditions like angina or congestive heart failure, as it may improve oxygen utilization and energy production in heart cells
The following are common factors that may support a claim: Diagnosis: patients who took a GLP-1 medication and later developed a serious digestive condition Severity of harm: patients who needed surgery, hospitalization, or ongoing care because of the condition Wrongful death: family members of someone who passed away after serious complications that may be linked to a GLP-1 medication Not every adverse reaction leads to a viable claim
Talk with your doctor or a registered dietitian about whether or not you should supplement with B12 and how much you should take.
Please click below for third-party testing results from the most recent batch of Lean Pre-Workout

These benefits have been demonstrated in large, well-designed cardiovascular outcome trials, including: Liraglutide (Victoza) the LEADER trial , which showed a significant reduction in cardiovascular death and all-cause mortality Semaglutide (Ozempic) the SUSTAIN-6 trial , demonstrating fewer major adverse cardiovascular events, particularly stroke Dulaglutide (Trulicity) the REWIND trial , which showed a significant reduction in major cardiovascular events even in people without established cardiovascular disease Tirzepatide (Mounjaro) cardiovascular outcome data from the SURPASS-CVOT programme are emerging, with early results suggesting cardiovascular benefit compared with insulin therapy These cardiovascular effects are a key reason why GLP-1based therapies are now recommended earlier in the treatment pathway for people with type 2 diabetes who have established heart disease or are at high cardiovascular risk
This means you will have more energy to work out and burn more calories